AnastrozoleAnastrozole-GH
Recommended OncologyRestrictedFirst-line line
Extension of restricted benefit listing to allow PBS-subsidised treatment of hormone-dependent early breast cancer in all post-menopausal women.
1
Submissions
1 resub
2005–05
On the record
$15k–45k
ICER range
1 sourced ICER · 2005
ICER stated
Cost basis
Decisions on record
- Meeting Nov 2014 Recommended Indication not stated
- Meeting Jul 2004 Recommended Used for the treatment of breast cancer no PSD
- Meeting Dec 2002 Recommended Treatment for breast cancer no PSD
Access path
- TGA registered · Anastrozole-GH
TGA label narrower than the PBS population
- Jul 2005Recommended · restricted
vs tamoxifen
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
The PBAC noted the mature ATAC trial results were presented and the new modelled economic evaluation presented an acceptable incremental cost per extra discounted quality-adjusted life-year gained in the range $15,000 - $45,000. PBAC · 2005
Cost-effectiveness accepted
Decision context
PopulationPost-menopausal women with hormone-dependent early breast cancer.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2005 | Recommended · restricted | tamoxifen | $15k–45k | RCT · DFS |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to early breast cancer first-line; TGA label includes adjuvant, first-line advanced, and post-tamoxifen advanced indications.